Yoshihiko Sakata

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata, Shinya Sakata, Yuko Oya et al. · European Journal of Cancer · 2021 · 81 citations

Real-world Setting, Medicine, Pathology +8

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

Go Saito, Yuko Oya, Yoshihiko Taniguchi et al. · Lung Cancer · 2021 · 53 citations

Durvalumab Consolidation Therapy, Medicine, Metronomic Therapy +9

The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment

Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado et al. · Lung Cancer · 2019 · 41 citations

Cancer Immunosurveillance, Medicine, Tumor Burden +7

[An early phase II study of CPT-11 in primary lung cancer].

Hiroyuki Nakai, M. Fukuoka, Kiyoyuki Furuse et al. · PubMed · 1991 · 38 citations

Health Sciences, Advanced Lung Disease, Medicine +13

Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis

Kodai Kawamura, Kazuya Ichikado, Makoto Takaki et al. · SpringerPlus · 2016 · 38 citations · Full text